Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 5Head & Neck 3Thoracic 2Sarcoma 2Endocrine 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1NET 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Thyroid Neoplasms 8Head and Neck Neoplasms 8Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Thyroid Cancer, Papillary 6Lung Neoplasms 6Sarcoma 5Colorectal Neoplasms 5Colonic Neoplasms 5Breast Neoplasms 5Thyroid Diseases 4Thoracic Neoplasms 4Salivary Gland Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neuroendocrine Tumors 4Neoplasms by Site 4Melanoma 4Lung Diseases 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Nasopharyngeal Carcinoma 3Glioma 3Endometrial Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Medullary 3

Interventions

trametinib 1pembrolizumab 1larotrectinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Biliary Tract Neoplasms × Head & Neck × Clear all
NCT02576431 2026-04-28

NAVIGATE

Bayer

Phase 2 Completed
215 enrolled 2 FDA
BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡